|
End-of-day quote
Buenos Aires S.E.
18/08/2026
|
5-day change | 1st Jan Change | ||
| 20,170.00 ARS | +3.22% |
|
+0.05% | +7.92% |
| 09:59am | GSK plc : Deutsche Bank remains Neutral | ZD |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 75.65B 154,179B 103B 88.31B 82.46B 142B 9,839B 145B 973B 381B 4,935B 387B 378B 16,316B | P/E 2026 * |
14.3x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 94.85B 193,309B 129B 111B 103B 178B 12,337B 181B 1,220B 478B 6,187B 485B 474B 20,457B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.69% | Yield 2027 * | 3.97% |
Last Transcript: GSK plc
| 1 day | +3.22% | ||
| 1 week | +0.05% | ||
| Current month | -1.32% | ||
| 1 month | -1.47% | ||
| 3 months | +8.38% | ||
| 6 months | -8.94% | ||
| Current year | +7.92% |
| 1 week | 19,360 |  | 20,270 |
| 1 month | 19,360 | | 22,300 |
| Current year | 17,020 | | 22,760 |
| 1 year | 12,975 | | 22,760 |
| 3 years | 6,390 | | 22,760 |
| 5 years | 2,171.5 | | 22,760 |
| 10 years | 543.12 | | 22,760 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.22% | +0.05% | - | - | 102B | |
| +3.97% | +3.97% | +80.42% | +130.66% | 1,093B | |
| +0.56% | +4.40% | +53.18% | +62.74% | 653B | |
| +1.65% | +5.42% | +27.19% | +74.65% | 458B | |
| +1.80% | +0.52% | +41.20% | +44.48% | 355B | |
| +1.24% | +2.35% | +25.99% | +41.24% | 294B | |
| +2.07% | +2.97% | +2.27% | +12.89% | 248B | |
| +3.07% | +5.04% | +47.91% | +67.68% | 230B | |
| +1.05% | -0.02% | -13.96% | -52.51% | 203B | |
| +2.66% | +8.07% | +24.45% | +93.35% | 178B | |
| Average | +2.10% | +1.20% | +32.07% | +52.80% | 412.27B | |
| Weighted average by Cap. | +2.25% | +1.45% | +45.92% | +72.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 69,174B 46.19B 39.62B 37B 63.83B 4,415B 64.88B 437B 171B 2,214B 173B 170B 7,321B | 35.54B 72,430B 48.36B 41.48B 38.74B 66.83B 4,622B 67.93B 457B 179B 2,318B 182B 178B 7,665B |
| Net income | 5.44B 11,078B 7.4B 6.34B 5.92B 10.22B 707B 10.39B 69.91B 27.37B 355B 27.77B 27.17B 1,172B | 6.48B 13,215B 8.82B 7.57B 7.07B 12.19B 843B 12.39B 83.4B 32.66B 423B 33.13B 32.41B 1,398B |
| Net Debt | 19.2B 39,130B 26.13B 22.41B 20.93B 36.11B 2,497B 36.7B 247B 96.7B 1,252B 98.1B 95.97B 4,141B | 16.37B 33,368B 22.28B 19.11B 17.85B 30.79B 2,130B 31.3B 211B 82.46B 1,068B 83.66B 81.84B 3,531B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/08/26 | ARS 20,170.00 | +3.22% | 689 |
| 14/08/26 | ARS 19,540.00 | -1.91% | 642 |
| 13/08/26 | ARS 19,920.00 | -0.15% | 236 |
| 12/08/26 | ARS 19,950.00 | -1.04% | 1,047 |
| 11/08/26 | ARS 20,160.00 | -2.18% | 296 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
